Cantor Fitzgerald Forecasts APLS FY2025 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will earn ($0.94) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $44.00 price objective on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share.

APLS has been the subject of a number of other research reports. Royal Bank of Canada reduced their price objective on Apellis Pharmaceuticals from $24.00 to $21.00 and set a "sector perform" rating for the company in a research note on Monday, April 21st. The Goldman Sachs Group decreased their price target on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Scotiabank raised their price objective on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the company a "sector perform" rating in a research note on Wednesday, April 2nd. HC Wainwright reissued a "buy" rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised their price target on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. Eight research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $45.28.

Apellis Pharmaceuticals Stock Up 1.3 %

Apellis Pharmaceuticals stock traded up $0.26 during midday trading on Wednesday, reaching $20.34. The stock had a trading volume of 2,221,961 shares, compared to its average volume of 2,170,426. The company has a fifty day moving average price of $21.84 and a two-hundred day moving average price of $27.37. Apellis Pharmaceuticals has a 12 month low of $16.98 and a 12 month high of $49.06. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The company has a market capitalization of $2.56 billion, a P/E ratio of -10.02 and a beta of 0.85.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $212.50 million during the quarter, compared to analysts' expectations of $197.92 million. During the same period last year, the company posted ($0.73) earnings per share. The business's quarterly revenue was up 45.2% on a year-over-year basis.

Insider Activity

In related news, General Counsel David O. Watson sold 5,569 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares in the company, valued at approximately $3,482,123. This represents a 3.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 6,115 shares of company stock valued at $154,684 in the last ninety days. 6.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in APLS. EverSource Wealth Advisors LLC raised its holdings in shares of Apellis Pharmaceuticals by 2,707.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock worth $25,000 after purchasing an additional 758 shares during the period. Signaturefd LLC raised its stake in shares of Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company's stock valued at $37,000 after buying an additional 918 shares during the period. GF Fund Management CO. LTD. lifted its position in shares of Apellis Pharmaceuticals by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company's stock valued at $70,000 after buying an additional 573 shares during the last quarter. US Bancorp DE grew its stake in shares of Apellis Pharmaceuticals by 70.0% during the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock worth $103,000 after acquiring an additional 1,327 shares during the period. Finally, Covestor Ltd increased its holdings in Apellis Pharmaceuticals by 1,819.2% in the 4th quarter. Covestor Ltd now owns 3,992 shares of the company's stock worth $127,000 after acquiring an additional 3,784 shares during the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).